Zacks and Needham downgrade Haemonetics earnings forecast and target price

Summary

Zacks Research has revised Haemonetics Co.'s EPS estimate for Q1 2026 from $1.11 to $1.03, with the yearly consensus now at $4.55. Needham has reduced the price target from $104 to $84, while Bank of America downgraded the stock rating from ‘Neutral’ to ‘Underperform’. The consensus rating remains ‘Moderate Buy’ with a target price of $97.89. The stock opened at $67.85, with a market cap of $3.26 billion and a P/E ratio of 26.71. Market Beat

Impact Analysis

1. Business Overview Analysis:

• Haemonetics is involved in providing blood management solutions, focusing its business model on medical devices and services to hospitals and blood centers.
• The company holds a strong position in the medical devices sector, with key competitive advantages such as specialized technology and a strong client base among healthcare providers.
• Recent events include a downward revision of EPS estimates and a series of analyst downgrades, which could indicate concerns about future revenue growth or operational challenges.

2. Financial Statement Analysis:

• Income Statement: Recent quarter showed a revenue decline of 3.7% year-over-year, but EPS increased from $0.90 to $1.24, suggesting improved profitability measures MSN.
• Balance Sheet: No specific balance sheet details provided, but the company’s P/E ratio of 26.71 suggests a valuation that may reflect growth expectations Market Beat.
• Cash Flow: No direct cash flow information available, but positive EPS surprise indicates efficient operational performance.
• Financial Ratios:
• Profitability: With an EPS increase, profitability ratios like ROE and ROA could be favorable, although exact metrics are not provided.
• Liquidity and Solvency: No specific data, but analyst downgrades may suggest perceived risks in these areas.
• Efficiency: Not directly discussed, but operational challenges could affect asset turnover ratios.

3. Valuation Assessment:

• The stock’s target price revisions and downgrades indicate potential overvaluation concerns. The current stock price reflects a P/E ratio that may not align with revised expectations.
• Potential catalysts affecting valuation could include changes in healthcare policies, competitive dynamics, or innovation in product offerings.

Overall, the revisions in financial estimates and analyst ratings suggest a cautious outlook on Haemonetics’ future performance, highlighting potential risks in achieving growth targets and maintaining market share.